Multiple opportunities across inflammatory indications
| Asset | Indication | IND | Phase 1 | Phase 2 | Phase 3 | Milestones |
|---|---|---|---|---|---|---|
| APX3330 | UC Ulcerative colitis |
SOLACE-1
|
|
|||
| APX3330 | UC Combo trial |
SOLACE-2
|
|
|||
| APX3330 | CD Post-surgical Crohn’s disease |
SERENE-1
|
|
|||
Pipeline compounds (e.g., APX2009, APX2014) or next-generation (undisclosed) compounds may be further explored in IBD or other indications.
Interested in learning more?
Contact our team for investor, partnership and clinical inquiries, or explore our published science.